Type 1 diabetes
-
Startup Syntax Bio Leverages CRISPR to Transform Cell Therapy Manufacturing
Syntax Bio’s technology platform uses CRISPR to direct stem cells to become a desired cell type in a process that’s more scalable and less expensive than current methods. The startup is raising a Series A round of financing to further demonstrate the potential of its technology.
-
A Startup Wins the First FDA Approval of a Cell Therapy for Type 1 Diabetes
CellTrans’s Lantidra is now the first FDA-approved cell therapy for type 1 diabetes. The therapy is made from islet cells sourced from deceased donors.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Eli Lilly to Buy Sigilon, Betting the Biotech Can Overcome a Cell Therapy Limitation
Eli Lilly is expanding its diabetes prospects by acquiring cell therapy developer Sigilon Therapeutics. The two companies are already partners in the development of a type 1 diabetes cell therapy currently in preclinical development.
-
Medtronic Gains FDA Approval for Newest Insulin Pump
Medtronic recently received FDA approval for its MiniMed 780G system, which is an insulin pump that automatically adjusts and corrects type 1 diabetes patients’ glucose levels every five minutes. The news comes two years after Medtronic submitted the system for FDA approval and three years after the company began selling the product in Europe.
-
Vertex Pays CRISPR Therapeutics $100M to Bring Gene-Editing to Type 1 Diabetes
Vertex Pharmaceuticals aims to use CRISPR Therapeutics’ gene-editing technology to develop type 1 diabetes cell therapies that don’t prompt the immune system to reject them. This approach could compete with a Sana Biotechnology program expected to reach its first test in humans this year.
-
StartUp Health Gains a New Investor and Adds a University
StartUp Health’s presence at ViVE will highlight the launch of its Health Transformer University and the addition of Helmsley Charitable Trust as an investor. Its pavilion will showcase 16 health tech companies and include panel discussions on remote patient monitoring, automation and more.
-
Provention Wins FDA Approval for First Drug to Delay Type 1 Diabetes Progression
Type 1 diabetes patients now have a new therapeutic option for the autoimmune disorder. Provention Bio drug Tzeild has received FDA approval for delaying the onset of the most severe stage of this chronic disease.
-
Vertex builds up pipeline of type 1 diabetes cell therapies with $320M buyout
Vertex Pharmaceuticals already has a cell therapy candidate for type 1 diabetes but the company says acquiring rival ViaCyte will provide it with complementary assets and technologies. The two companies already share a partner in common: both have therapeutic candidates that use the gene-editing capabilities of CRISPR Therapeutics.
-
Code Bio corrals $75M to skip viruses, use synthetic DNA for genetic meds delivery
Code Biotherapeutics uses synthetic DNA as the foundation for its genetic medicines, which the startup claims offer several key advantages compared to genetic medicines delivered via engineered viruses. The startup plans to use its new capital to develop lead programs in Duchenne muscular dystrophy and type 1 diabetes.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Imagine a world without disease
The team behind the World Without Disease Accelerator, part of Janssen Research & Development, one of the Janssen Pharmaceutical companies of Johnson & Johnson, is embracing an ambitious paradigm focused on disease prevention, interception and cure.
-
Provention Bio drug for delaying type 1 diabetes hit with FDA delay of its own
Provention Bio needs to show the FDA that the drug substance produced from its contract manufacturer is comparable to the Eli Lilly-made drug substance that was evaluated in clinical trials. A larger study testing the prospective type 1 diabetes therapy teplizumab is ongoing and could provide the information the agency needs.
-
Devices & Diagnostics, Health Tech
Dexcom and Livongo partner to allow glucose data to be synced on Livongo platform
Medical device maker Dexcom is partnering with Livongo such that users of Livongo that have diabetes and use Dexcom’s continuous glucose monitoring system can sync their data on the Livongo platform.
-
Devices & Diagnostics, Patient Engagement
Dexcom’s IT outage shows fabulous device maker floundering with patient communication
Scores of users took to Facebook to express their dismay, frustration and anger at Dexcom when the CGM device company failed to properly keep them updated after an IT outage prevented type 1 diabetes patients from sharing data.
-
Vertex buys developer of preclinical cell therapy for Type 1 diabetes for $950M
The Boston-based company said it would acquire Semma Therapeutics, which is developing a stem cell-derived therapy and device for the disease. Preclinical data were announced in July, and clinical trials are planned for 2020.
-
Devices & Diagnostics, Artificial Intelligence
Powered by AI, Medtronic’s Sugar.IQ diabetes assistant shows better outcomes
Medtronic announced data at the annual meeting of the American Diabetes Association on Monday that shows that people using its AI-powered Sugar.IQ diabetes assistant have better control of their blood glucose levels.